Metrizamide inhibits human brain hexokinase

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The myelographic contrast agent, metrizamide, causes a temporary confusional state in many patients. Since metrizamide is a 2-deoxyglucose analogue, it was tested for inhibitory effects on glucose metabolism. The Michaelis constant (Km) of human brain hexokinase for glucose rose from 0.039 to 0.24 and 0.47 mM with final metrizamide concentrations of 0,16, and 32 mM, respectively. The maximal velocity did not change. Since metrizamide is injected into the human CSF in concentrations of up to 780 mM, impairment of brain glucose metabolism can be expected. These effects could be largely counteracted if metrizamide were injected in a 100 mM glucose solution.

Original languageEnglish (US)
Pages (from-to)884-887
Number of pages4
JournalNeurology
Volume32
Issue number8
StatePublished - Jan 1 1982

Fingerprint

Metrizamide
Hexokinase
Brain
Glucose
Confusion
Deoxyglucose
Contrast Media

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Metrizamide inhibits human brain hexokinase. / Bertoni, John M.

In: Neurology, Vol. 32, No. 8, 01.01.1982, p. 884-887.

Research output: Contribution to journalArticle

Bertoni, John M. / Metrizamide inhibits human brain hexokinase. In: Neurology. 1982 ; Vol. 32, No. 8. pp. 884-887.
@article{c7a2d529e8ae4a6fa3cf7f641e14e97d,
title = "Metrizamide inhibits human brain hexokinase",
abstract = "The myelographic contrast agent, metrizamide, causes a temporary confusional state in many patients. Since metrizamide is a 2-deoxyglucose analogue, it was tested for inhibitory effects on glucose metabolism. The Michaelis constant (Km) of human brain hexokinase for glucose rose from 0.039 to 0.24 and 0.47 mM with final metrizamide concentrations of 0,16, and 32 mM, respectively. The maximal velocity did not change. Since metrizamide is injected into the human CSF in concentrations of up to 780 mM, impairment of brain glucose metabolism can be expected. These effects could be largely counteracted if metrizamide were injected in a 100 mM glucose solution.",
author = "Bertoni, {John M}",
year = "1982",
month = "1",
day = "1",
language = "English (US)",
volume = "32",
pages = "884--887",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Metrizamide inhibits human brain hexokinase

AU - Bertoni, John M

PY - 1982/1/1

Y1 - 1982/1/1

N2 - The myelographic contrast agent, metrizamide, causes a temporary confusional state in many patients. Since metrizamide is a 2-deoxyglucose analogue, it was tested for inhibitory effects on glucose metabolism. The Michaelis constant (Km) of human brain hexokinase for glucose rose from 0.039 to 0.24 and 0.47 mM with final metrizamide concentrations of 0,16, and 32 mM, respectively. The maximal velocity did not change. Since metrizamide is injected into the human CSF in concentrations of up to 780 mM, impairment of brain glucose metabolism can be expected. These effects could be largely counteracted if metrizamide were injected in a 100 mM glucose solution.

AB - The myelographic contrast agent, metrizamide, causes a temporary confusional state in many patients. Since metrizamide is a 2-deoxyglucose analogue, it was tested for inhibitory effects on glucose metabolism. The Michaelis constant (Km) of human brain hexokinase for glucose rose from 0.039 to 0.24 and 0.47 mM with final metrizamide concentrations of 0,16, and 32 mM, respectively. The maximal velocity did not change. Since metrizamide is injected into the human CSF in concentrations of up to 780 mM, impairment of brain glucose metabolism can be expected. These effects could be largely counteracted if metrizamide were injected in a 100 mM glucose solution.

UR - http://www.scopus.com/inward/record.url?scp=0020045715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020045715&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 884

EP - 887

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -